Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back
Evaluation ViewAttendees 7

Immunizations/Delivery

Session: Immunizations/Delivery

Impact of Multi-Level Interventions to Improve Human Papillomavirus Vaccine Uptake on Other Adolescent Vaccines Due

Saturday, May 4, 2024
8:30 AM – 8:45 AM ET
Location: Metro Toronto Convention Centre: 201 F
CE Enduring CME: 0.25
Publication Number: 2105.3
Robert M. Jacobson, Mayo Clinic College of Medicine and Science, Rochester, MN, United States; Gregory Jenkins, Mayo Clinic, Rochester, MN, United States; Jeph Herrin, Flying Buttress Associates, Charlottesville, VA, United States; Jennifer St. Sauver, Mayo Clinic Alix School of Medicine, Rochester, MN, United States; Joan M. Griffin, Mayo Clinic Alix School of Medicine, Rochester, MN, United States; Lila J. Finney Rutten, Mayo Clinic, Rochester, MN, United States

    Presenting Author(s)

  • RJ

    Robert M. Jacobson, M.D., F.A.A.P. (he/him/his)

    Professor of Pediatrics
    Mayo Clinic College of Medicine and Science
    Rochester, Minnesota, United States

    Slides
Disclosure(s):
Robert M. Jacobson, M.D., F.A.A.P.: 3M Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbott Laboratories (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbvie Inc. (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Adobe Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Baxter Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Becton Dickinson & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Embecta Corp (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Hubbell Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Johnson & Johnson (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Lily Eli & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Medtronic Plc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Merck & Co (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Moderna Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Optum Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); RPM Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Takeda Pharma Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimmer Biomet Hldgs (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimvie (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)